Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.5K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT.

European urology oncology·2026
Same author

A multi-modal flow phantom for quantitative PET/Spectral CT.

bioRxiv : the preprint server for biology·2026
Same author

"Where are They Now?": A Single Institution's 10-Years Experience with an Integrated Nuclear Radiology Fellowship.

Academic radiology·2026
Same author

Correction: Acalculous cholecystitis- an imaging and therapeutic update.

Abdominal radiology (New York)·2026
Same author

Discovery of a Thermostable Nigerose Phosphorylase for the Efficient Chemoenzymatic Radiosynthesis of a <i>S. aureus</i>-Targeted <sup>18</sup>F-Disaccharide.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Evaluation of radiation damage effects of low-energy Auger and conversion electrons emitted by <sup>134</sup>Ce decay using a Monte Carlo method.

Scientific reports·2026

Related Experiment Video

Updated: Aug 26, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K

177Lu-PSMA Therapy.

Ephraim E Parent1, Bital Savir-Baruch2, Isis W Gayed3

  • 1Department of Radiology, Mayo Clinic, Jacksonville, Florida.

Journal of Nuclear Medicine Technology
|October 10, 2022
PubMed
Summary
This summary is machine-generated.

Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) therapy offers an effective new treatment for prostate cancer. This targeted radiopharmaceutical therapy has shown clear benefits in clinical trials and is poised for wider adoption.

Keywords:
genitourinaryprostateradiation safetyradionuclide therapyradiopharmaceutical therapytechnology

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

329

Related Experiment Videos

Last Updated: Aug 26, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

329

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Prostate-specific membrane antigen (PSMA) targeted PET imaging has proven successful.
  • 177Lu-PSMA therapy leverages this targeting for effective treatment delivery.
  • This therapy has demonstrated significant benefits in large prospective clinical trials.

Purpose of the Study:

  • To review the evidence supporting 177Lu-PSMA therapy for prostate cancer.
  • To highlight ongoing research and areas under investigation.
  • To provide practical information for implementing this treatment.

Main Methods:

  • Review of clinical trial data and scientific literature.
  • Discussion of technological aspects of 177Lu-PSMA administration.
  • Outline of practical considerations for patient care.

Main Results:

  • 177Lu-PSMA therapy is an effective treatment for prostate cancer, recently FDA-approved.
  • The therapy has demonstrated clear benefits in prospective clinical trials.
  • It is expected to become a standard treatment option.

Conclusions:

  • 177Lu-PSMA therapy represents a significant advancement in prostate cancer treatment.
  • Successful implementation requires multidisciplinary collaboration.
  • Further research is exploring its full potential and applications.